Achieve Life Sciences, Inc.: retained earnings or deficit
Retained earnings or deficit for Achieve Life Sciences, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Achieve Life Sciences, Inc. financial histories
What this measure means
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
Exact concept: us-gaap:RetainedEarningsAccumulatedDeficit. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | -260,226,000 | USD | 2026-03-24 | 10-K · 0001193125-26-120690 |
| At date | 2024-12-31 | -205,578,000 | USD | 2026-03-24 | 10-K · 0001193125-26-120690 |
| At date | 2023-12-31 | -165,751,000 | USD | 2025-03-11 | 10-K · 0000950170-25-036831 |
| At date | 2022-12-31 | -135,936,000 | USD | 2024-03-28 | 10-K · 0000950170-24-038049 |
| At date | 2021-12-31 | -93,586,000 | USD | 2023-03-16 | 10-K · 0001564590-23-003800 |
| At date | 2020-12-31 | -60,434,000 | USD | 2022-03-10 | 10-K · 0001564590-22-009485 |
| At date | 2019-12-31 | -45,704,000 | USD | 2021-03-11 | 10-K · 0001564590-21-012523 |
| At date | 2018-12-31 | -25,381,000 | USD | 2020-03-13 | 10-K · 0001564590-20-010642 |
| At date | 2017-12-31 | -12,694,000 | USD | 2019-03-14 | 10-K · 0001564590-19-007838 |
| At date | 2016-12-31 | -2,062,000 | USD | 2018-03-01 | 10-K · 0001564590-18-004159 |
| At date | 2015-12-31 | -176,811,000 | USD | 2017-02-23 | 10-K · 0001564590-17-002109 |
| At date | 2014-12-31 | -159,958,000 | USD | 2016-03-09 | 10-K · 0001564590-16-014302 |
| At date | 2013-12-31 | -133,689,000 | USD | 2015-03-26 | 10-K · 0001564590-15-002010 |
| At date | 2012-12-31 | -101,840,000 | USD | 2014-03-11 | 10-K · 0001193125-14-093757 |
| At date | 2011-12-31 | -80,742,000 | USD | 2013-03-07 | 10-K · 0001193125-13-096041 |
| At date | 2010-12-31 | -66,069,000 | USD | 2012-03-08 | 10-K · 0001193125-12-103884 |
Related financial histories
- Achieve Life Sciences, Inc.: total assets
- Achieve Life Sciences, Inc.: total liabilities
- Achieve Life Sciences, Inc.: stockholders equity
- Achieve Life Sciences, Inc.: cash and cash equivalents
- Achieve Life Sciences, Inc.: net income or loss
- Achieve Life Sciences, Inc.: operating cash flow
- Achieve Life Sciences, Inc.: capital expenditure payments
- Achieve Life Sciences, Inc.: financing cash flow
- Achieve Life Sciences, Inc.: investing cash flow
- Achieve Life Sciences, Inc.: basic weighted-average shares
- Achieve Life Sciences, Inc.: diluted weighted-average shares
- Achieve Life Sciences, Inc.: basic earnings per share
- Achieve Life Sciences, Inc.: diluted earnings per share
- Achieve Life Sciences, Inc.: income tax expense or benefit
- Achieve Life Sciences, Inc.: net property, plant and equipment
- Achieve Life Sciences, Inc.: share-based compensation expense
- Achieve Life Sciences, Inc.: current assets
- Achieve Life Sciences, Inc.: current liabilities
- Achieve Life Sciences, Inc.: current accounts payable
- Achieve Life Sciences, Inc.: net finite-lived intangible assets
- Achieve Life Sciences, Inc.: net current accounts receivable
- Achieve Life Sciences, Inc.: operating expenses
- Achieve Life Sciences, Inc.: research and development expense
Inspect the source
- Entity
- Achieve Life Sciences, Inc. / CIK 0000949858
- Captured
- 2026-09-20T05:10:47.545Z
- SEC response SHA-256
99bc74bd7159630b925b01f21dc60b0899467b369bb5a1524cbbfa411e86b911
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000949858.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))